For research use only. Not for therapeutic Use.
Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.<br>Solifenacin succinate is a new muscarinic receptor antagonist developed for the treatment of overactive bladder. The affinity constants (pKi) of solifenacin for recombinant human muscarinic M1, M2 and M3 receptors are 7.6, 6.9 and 8.0, respectively. Hence, the muscarinic M3 receptor subtype selectivity of solifenacin over the muscarinic M2 receptor subtype is readily apparent, but is only marginal over the muscarinic M1 receptor subtype. In the same study, solifenacin and oxybutynin inhibit muscarinic M3 receptor-mediated intracellular Ca2+ mobilization in bladder smooth muscle cells isolated from guinea pigs and in submandibular gland cells isolated from mice.
| Catalog Number | A000379 |
| CAS Number | 242478-38-2 |
| Synonyms | YM905 |
| Molecular Formula | C23H26N2O2 • C4H6O4 |
| Purity | ≥95% |
| Target | Muscarinic Receptor |
| Solubility | >24.1mg/mL in DMSO |
| Storage | 3 years -20C powder |
| InChIKey | RXZMMZZRUPYENV-VROPFNGYSA-N |
